BR112022016492A2 - Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2 - Google Patents
Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2Info
- Publication number
- BR112022016492A2 BR112022016492A2 BR112022016492A BR112022016492A BR112022016492A2 BR 112022016492 A2 BR112022016492 A2 BR 112022016492A2 BR 112022016492 A BR112022016492 A BR 112022016492A BR 112022016492 A BR112022016492 A BR 112022016492A BR 112022016492 A2 BR112022016492 A2 BR 112022016492A2
- Authority
- BR
- Brazil
- Prior art keywords
- cov
- sars
- rbd
- subunit
- ndv
- Prior art date
Links
- 241000711404 Avian avulavirus 1 Species 0.000 title abstract 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 3
- 230000003472 neutralizing effect Effects 0.000 abstract 2
- 241000699800 Cricetinae Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2. a presente invenção refere-se à obtenção de duas vacinas vivas recombinantes ou vetorizadas de ndv que expressam a subunidade s1 e rbd da proteína s do sars-cov-2, que, quando aplicada por via intranasal em modelo animal de hamster, gera a produção de anticorpos neutralizantes contra sars- cov-2. a invenção mostra ainda que essas vacinas vivas são compatíveis para seu uso combinado entre si, para induzir a produção de anticorpos neutralizantes contra sars-cov-2 sem interferência cruzada substancial, indicando uma sinergia entre ambas vacinas, onde os vírus recombinantes de ndv (rndv-ls1-hn-rbd/sars-cov-2 (seq id no. 7) e rndv-ls1-s1-f/sars-cov-2 (seq id no. 13)), conseguem expressar a subunidade s1 e rbd da proteína s de sars-cov-2 em mamíferos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PE2021000033A PE20210318A1 (es) | 2021-01-08 | 2021-01-08 | Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2 |
PCT/IB2022/050031 WO2022149058A1 (es) | 2021-01-08 | 2022-01-04 | Composición inmunogénica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteína spike del sars-cov-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016492A2 true BR112022016492A2 (pt) | 2023-10-31 |
Family
ID=74855966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016492A BR112022016492A2 (pt) | 2021-01-08 | 2022-01-04 | Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2 |
Country Status (7)
Country | Link |
---|---|
AR (1) | AR124522A1 (pt) |
BR (1) | BR112022016492A2 (pt) |
CO (1) | CO2022010353A2 (pt) |
EC (1) | ECSP22064620A (pt) |
MX (1) | MX2022004220A (pt) |
PE (1) | PE20210318A1 (pt) |
WO (1) | WO2022149058A1 (pt) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA016217B1 (ru) * | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
WO2021229270A1 (es) * | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
CN112011521A (zh) * | 2020-06-15 | 2020-12-01 | 浙江迪福润丝生物科技有限公司 | 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用 |
-
2021
- 2021-01-08 PE PE2021000033A patent/PE20210318A1/es unknown
- 2021-12-28 AR ARP210103681A patent/AR124522A1/es unknown
-
2022
- 2022-01-04 BR BR112022016492A patent/BR112022016492A2/pt unknown
- 2022-01-04 WO PCT/IB2022/050031 patent/WO2022149058A1/es active Application Filing
- 2022-01-04 MX MX2022004220A patent/MX2022004220A/es unknown
- 2022-07-22 CO CONC2022/0010353A patent/CO2022010353A2/es unknown
- 2022-08-17 EC ECSENADI202264620A patent/ECSP22064620A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20210318A1 (es) | 2021-02-16 |
WO2022149058A1 (es) | 2022-07-14 |
AR124522A1 (es) | 2023-04-05 |
MX2022004220A (es) | 2022-08-08 |
ECSP22064620A (es) | 2022-09-30 |
CO2022010353A2 (es) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0707300A8 (pt) | Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
BRPI1015917A2 (pt) | antígenos de rsv recombinantes. | |
BR112019021824A2 (pt) | Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio | |
BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
NZ627888A (en) | Materials and methods for respiratory disease control in canines | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
BR112022019949A2 (pt) | Vacina com base em vetor de poxvírus atenuado para proteção contra covid-19 | |
BR112022022604A2 (pt) | Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos | |
MX2019003156A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
Xu et al. | Differential modulation of avian β-defensin and Toll-like receptor expression in chickens infected with infectious bronchitis virus | |
BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
BR112022016507A2 (pt) | Vacinas contra o coronavírus e métodos de uso | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
AR067830A1 (es) | Proteinas streptococcus inmunogenicas | |
BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 | |
MX2022012251A (es) | Vacuna universal contra la influenza usando arnm modificado con nucleósidos. | |
BR112015023738A2 (pt) | vacinas de nucleoproteina influenza | |
CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
BR112022016492A2 (pt) | Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2 | |
AR085800A1 (es) | Vacuna de rinitis equina | |
MX2021011439A (es) | Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente. | |
BR112022011422A2 (pt) | Imunógenos para vírus da caxumba e do sarampo e seus usos |